Literature DB >> 16357568

Oncogenic PI3K and its role in cancer.

Yardena Samuels1, Kajsa Ericson.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to examine the contribution of the PI3K signaling pathway to the development of human tumors and to propose further studies to elucidate how to develop therapeutics for patients with mutations in this pathway. RECENT
FINDINGS: More than 30% of various solid tumor types were recently found to contain mutations in PIK3CA, the catalytic subunit of PI3K. Further analysis of key genes in this pathway identified an additional eight genes altered in tumors. These were generally found to be mutated in a mutually exclusive manner, thus increasing the mutation frequency of the pathway to 40% in colorectal cancers and emphasizing the importance of the PI3K pathway in tumorigenesis. Functional analyses of PIK3CA mutations revealed that they increase its enzymatic activity, stimulate AKT signaling, allow growth factor-independent growth as well as increasing cell invasion and metastasis.
SUMMARY: The PI3K signaling pathway is dysregulated by a variety of mechanisms in a large fraction of human tumors. Both mutational and functional analyses have shown that PIK3CA is an oncogene that plays an important role in tumor progression. Mutant members of the PI3K pathway, including PIK3CA, are good targets for therapeutic intervention because most of them are kinases, making them attractive for drug development. Gaining further insights into PIK3CA oncogenic mechanisms may produce new biomarkers and help the development of targeted therapeutics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16357568     DOI: 10.1097/01.cco.0000198021.99347.b9

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  186 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

2.  Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase.

Authors:  Minghao Sun; Jonathan R Hart; Petra Hillmann; Marco Gymnopoulos; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

3.  Hepatic vitamin A preloading reduces colorectal cancer metastatic multiplicity in a mouse xenograft model.

Authors:  Eun Young Park; Daniel Pinali; Krista Lindley; Michelle A Lane
Journal:  Nutr Cancer       Date:  2012-05-29       Impact factor: 2.900

Review 4.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

Review 5.  Defining the cancer master switch.

Authors:  Courtney J Balentine; David H Berger; Shi-He Liu; Changyi Chen; John Nemunaitis; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

6.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK.

Authors:  Marius Grzelinski; Florian Steinberg; Tobias Martens; Frank Czubayko; Katrin Lamszus; Achim Aigner
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain.

Authors:  Joseph J Falke
Journal:  Cellscience       Date:  2007

8.  A phosphoinositide 3-kinase (PI3K)-serum- and glucocorticoid-inducible kinase 1 (SGK1) pathway promotes Kv7.1 channel surface expression by inhibiting Nedd4-2 protein.

Authors:  Martin Nybo Andersen; Katarzyna Krzystanek; Frederic Petersen; Sofia Hammami Bomholtz; Søren-Peter Olesen; Hugues Abriel; Thomas Jespersen; Hanne Borger Rasmussen
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

Review 9.  Targeting the PI3K signaling pathway in cancer.

Authors:  Kwok-Kin Wong; Jeffrey A Engelman; Lewis C Cantley
Journal:  Curr Opin Genet Dev       Date:  2009-12-16       Impact factor: 5.578

Review 10.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.